Table 1.
Baseline demographic information and medication status
| Variable | Total (n=117) | RP (+) (n=20) | RP (−) (n=97) | p-value |
|---|---|---|---|---|
| Age (yr) | 57 (49~65) | 55 (46~63) | 57 (49~66) | 0.411 |
| Female | 102 (87.2) | 17 (85.0) | 85 (87.6) | 0.720 |
| Body mass index (kg/m2) | 22.8 (20.6~24.9) | 22.4 (20.7~24.3) | 22.9 (20.6~25.0) | 0.728 |
| Disease duration (yr) | 6 (1~13) | 7 (3~14) | 5 (1~13) | 0.606 |
| X-ray f/u duration (mo) | 15 (13~19) | 16 (13~23) | 15 (13~19) | 0.588 |
| Smoking | 1 (0.9) | 1 (5.0) | 0 (0) | 0.171 |
| Medication status | ||||
| Glucocorticoid use | 88 (75.2) | 13 (65.0) | 75 (77.3) | 0.263 |
| Pd equivalent (mg) | 5.0 (2.5~5.0) | 5.0 (2.5~7.5) | 5.0 (2.5~5.0) | 0.378 |
| csDMARDs | ||||
| Methotrexate | 73 (62.4) | 13 (65.0) | 60 (61.9) | 0.792 |
| Leflunomide | 55 (47.0) | 11 (55.0) | 44 (45.4) | 0.432 |
| Hydroxychloroquine | 62 (53.0) | 12 (60.0) | 50 (51.5) | 0.490 |
| Sulfasalazine | 7 (6.0) | 0 (0) | 7 (7.2) | 0.602 |
| bDMARDs or tsDMARDs | 55 (47.0) | 11 (55.0) | 44 (45.4) | 0.432 |
| Tocilizumab | 25 | 6 | 19 | |
| Abatacept | 18 | 3 | 15 | |
| Etanercept | 4 | 0 | 4 | |
| Adalimumab | 3 | 0 | 3 | |
| Tofacitinib | 3 | 2 | 1 | |
| Baricitinib | 2 | 0 | 2 | |
| DAS28 status* | ||||
| Remission | 49 (41.9) | 6 (20.0) | 43 (44.3) | |
| LDA | 17 (14.5) | 3 (15.0) | 13 (14.4) | |
| MDA | 32 (27.4) | 6 (30.0) | 26 (26.8) | |
| HDA | 19 (16.2) | 4 (20.0) | 15 (15.5) | |
| MDA or HDA | 51 (43.6) | 10 (50.0) | 41 (42.3) | 0.525 |
| DAS28 change† | ||||
| Stable | 72 (61.5) | 14 (70.0) | 58 (59.8) | |
| Improvement | 38 (32.5) | 5 (25.0) | 33 (34.0) | |
| Deterioration | 7 (6.0) | 1 (5.0) | 6 (6.2) | |
| Target achievement‡ | 96 (82.1) | 14 (70.0) | 82 (84.5) | 0.196 |
Values are presented as median (interquartile range) or number (%). RP: radiographic progression, f/u: follow up, Pd: prednisolone, csDMARDs: conventional synthetic disease modifying anti-rheumatic drugs, bDMARDs: biologic disease modifying anti-rheumatic drugs, tsDMARDs: targeted synthetic disease modifying anti-rheumatic drugs, DAS28: disease activity score with 28 joint counts, LDA: low disease activity, MDA: moderate disease activity, HDA: high disease activity, ESR: erythrocyte sedimentation rate. *DAS28 status was evaluated at baseline and remission, LDA, MDA, and HDA were defined according to DAS28-ESR. †DAS28 changes defined as ‘Stable’ indicate no interval change in the DAS28 during the study period. ‘Improvement’ denotes a change from MDA or HDA to remission or LDA during the study periods. ‘Deterioration’ denotes a change from remission or LDA to MDA or HDA. ‡Target achievement is defined as achievement of remission or LDA at the last visit.